Resumo
Objetivo: Reunir informações relativas ao complexo Acinetobacter baumannii - calcoaceticus, características, virulência e resistência. Caracterizar genes ligados a estes fatores, abordar o aumento da resistência bacteriana aos antimicrobianos. Revisão bibliográfica: Acinetobacter é um dos patógenos mais frequentes em casos de Infecções Associadas à Assistência a Saúde, com alta prevalência de isolados multidroga resistentes. A. baumannii foi uma das espécies bacterianas mais incidentes durante a pandemia da COVID-19. Fatores de virulência permitem a sobrevivência em ambientes abióticos favorecendo ocorrência em hospitais. Isolados resistentes produtores de betalactamases relatados em todo o mundo. Os aminoglicosídeos tornaram-se uma opção, entretanto a resistência ao fármaco o tornou ineficiente entre 50/87% dos isolados. As tetraciclinas mostravam-se eficazes com resistência variável, menos de 20% na Europa e superiores a 70% no continente Africano. As polimixinas B e E voltaram a ser utilizadas, mas o uso contínuo do fármaco tem aumentado o número de isolados resistentes. Assim, terapêutica com combinação de fármacos é amplamente estudada, as divergências entre estudos impossibilitam a padronização da terapêutica. Considerações finais: A alta capacidade de Acinetobacter se manter em ambientes hospitalares e a alta incidência de isolados MDR aliada a dificuldade de estabelecer protocolos para o tratamento tornam críticas a busca por opções terapêuticas.
Referências
ANVISA, Agência Nacional de Vigilância Sanitária. Plano nacional para a prevenção e o controle de resistência microbiana nos serviços de saúde. 2017.
ANVISA, Agência Nacional de Vigilância Sanitária. NOTA TÉCNICA GVIMS/GGTES/ANVISA No 02/2015 Orientações gerais para a implantação da Sub-rede Analítica de Resistência Microbiana em Serviços de Saúde. 2015.
BHANDARI S, et al. Biofilm formation capacity and Carbapenem-resistance in Acinetobacter-calcoaceticus-baumannii isolated from inpatients in a tertiary care hospital in Nepal. BMC Research Notes, 2025; 18(1): 225.
BORCAN AM, et al. Trends in Antimicrobial Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa from Bloodstream Infections: An Eight-Year Study in a Romanian Tertiary Hospital. Pharmaceuticals, 2025; 18(7): 948.
BOSTANGHADIRI N, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control, 2024; 13(1): 24.
CASTANHEIRA M, et al. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clinical Infectious Diseases, 2023; 76(Supplement_2): S166-S178.
CHOUDHARY J, SHARIFF M. Characterization of carbapenem-resistant biofilm forming Acinetobacter baumannii isolates from clinical and surveillance samples. Scientific Reports, 2025; 15(1): 33892.
CONCEIÇÃO-NETO C, et al. Detection of the plasmid-mediated mcr-1 gene in clinical KPC-2-producing Escherichia coli isolates in Brazil. International Journal of Antimicrobial Agents, 2017; 50(2): 282.
COSGAYA C, et al. In vitro and in vivo Virulence Potential of the Emergent Species of the Acinetobacter baumannii (Ab) Group. Frontiers in microbiology, 2019; 10: 2429.
DURANTE-MANGONI E, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clinical Infectious Diseases, 2013; 57(3): 349-358.
EL HAFA H, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii strains carrying the blaGES, blaNDM and blaOXA23 in Morocco. Germs, 2019; 9(3): 133.
FALAGAS ME, et al. Global epidemiology and antimicrobial resistance of Metallo-β-Lactamase (MBL)-producing Acinetobacter clinical isolates: a systematic review. Pathogens, 2025; 14(6): 557.
GALLARDO-GODOY A, et al. Structure-Function Studies of Polymyxin B Lipononapeptides. Molecules, 2019; 24(3): 553.
GROSSMAN TH. Tetracycline antibiotics and resistance. Cold Spring Harbor Perspectives in Medicine, 2016; 6(4): a025387.
GUO Y, et al. Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report. One Health Advances, 2025; 3(1): 23.
HARDING CM, et al. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nature Reviews Microbiology, 2018; 16(2): 91-102.
HARMER CJ, et al. Acinetobacter baumannii GC2 Sublineage Carrying the aac(6')-Im Amikacin, Netilmicin, and Tobramycin Resistance Gene Cassette. Antimicrobial Agents and Chemotherapy, 2023; 67(8): e00486-23.
IYER R, et al. Acinetobacter baumannii OmpA is a selective antibiotic permeant porin. ACS Infectious Diseases, 2017; 4(3): 373-381.
JIE J, et al. Prognostic Indicators of Carbapenem‐Resistant Acinetobacter baumannii Infection: A Meta‐Analysis and Systematic Review. Health Science Reports, 2025; 8(12): e71639.
KAVIAR VH, et al. Antibiotic resistance pattern and biofilm formation among clinical Acinetobacter baumannii isolates: A cross-sectional study. Journal of Acute Disease, 2025; 1(41): 5.
KINOSHITA Y, et al. Study of the structure-activity relationship of polymyxin analogues. Bioorganic & Medicinal Chemistry Letters, 2018; 28(16): 2713-2716.
LAPLANTE KL, et al. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine, 2022; 54(1): 1686-1700.
MANDAL SM, PAUL D. Bacterial Adaptation to Co-resistance. Springer: Cham, 2020.
MARINOVA-BULGARANOVA T, et al. Current Methods for Reliable Identification of Species in the Acinetobacter calcoaceticus–Acinetobacter baumannii Complex. Microorganisms, 2025; 13(8): 1819.
MEA HJ, et al. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiological research, 2021; 247: 126722.
NADERI G, et al. Mobile genetic elements carrying aminoglycoside resistance genes in Acinetobacter baumannii isolates belonging to global clone 2. Frontiers in Microbiology, 2023; 14: 1172861.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization: Genebra, 2019.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization: Genebra, 2025.
PAUL M, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The Lancet Infectious Diseases, 2018; 18(4): 391-400.
PIPERAKI ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clinical Microbiology and Infection, 2019; 25(8): 951-957.
PROCOP GW, et al. Koneman Diagnóstico Microbiológico: texto e atlas. 7. ed. Guanabara Koogan: Rio de Janeiro-RJ, 2018.
QIN Q, et al. Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections. Pathogens, 2024; 13(12): 1049.
RAJKUMARI S, et al. Prevalence and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital. Journal of College of Medical Sciences-Nepal, 2020; 16(1): 26-32.
SEOK H, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB): A multicentre study in Korea. Journal of Global Antimicrobial Resistance, 2021; 24: 429-439.
TAMMA PD, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases, 2024; 78(5): e1-e40.
VILLALÓN P et al. Dynamics of a sporadic nosocomial Acinetobacter calcoaceticus–Acinetobacter baumannii complex population. Frontiers in microbiology, 2019; 10: 593.
YEHYA A, et al. The intricacies of Acinetobacter baumannii: a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications. Frontiers in microbiology, 2025; 16: 1565965.
ZARRILLI R et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy. Ann Ig, 2021; 33(5): 401-9.
